Published in Cancer Res on April 16, 2015
Grapefruit-derived nanovectors deliver miR-18a for treatment of liver metastasis of colon cancer by induction of M1 macrophages. Oncotarget (2016) 0.82
Exosomes miR-126a released from MDSC induced by DOX treatment promotes lung metastasis. Oncogene (2016) 0.80
Edible Ginger-derived Nano-lipids Loaded with Doxorubicin as a Novel Drug-delivery Approach for Colon Cancer Therapy. Mol Ther (2016) 0.79
Grapefruit-derived Nanovectors Delivering Therapeutic miR17 Through an Intranasal Route Inhibit Brain Tumor Progression. Mol Ther (2015) 0.79
Targeting Immune Regulatory Networks to Counteract Immune Suppression in Cancer. Vaccines (Basel) (2016) 0.79
Potential functional applications of extracellular vesicles: a report by the NIH Common Fund Extracellular RNA Communication Consortium. J Extracell Vesicles (2015) 0.78
Plant derived edible nanoparticles as a new therapeutic approach against diseases. Tissue Barriers (2016) 0.76
Drug delivery: Leukocyte-like carriers. Nat Mater (2016) 0.75
Delivery of a chemotherapeutic drug using novel hollow carbon spheres for esophageal cancer treatment. Int J Nanomedicine (2017) 0.75
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release (2000) 14.89
Cancer and the chemokine network. Nat Rev Cancer (2004) 10.27
Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol (2011) 9.68
Evolving functions of endothelial cells in inflammation. Nat Rev Immunol (2007) 4.94
Cellular pH gradient in tumor versus normal tissue: potential exploitation for the treatment of cancer. Cancer Res (1996) 3.11
Tuning inflammation and immunity by chemokine sequestration: decoys and more. Nat Rev Immunol (2006) 2.92
Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain. Mol Ther (2011) 2.61
The role of chemokines in the microenvironmental control of T versus B cell arrest in Peyer's patch high endothelial venules. J Exp Med (2000) 2.35
Organ selectivity in metastasis: regulation by chemokines and their receptors. Clin Exp Metastasis (2007) 2.18
Crossing the endothelial barrier during metastasis. Nat Rev Cancer (2013) 2.00
Overcoming hurdles in developing successful drugs targeting chemokine receptors. Nat Rev Immunol (2011) 1.91
Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. Nat Nanotechnol (2012) 1.85
Tumoritropic and lymphotropic principles of macromolecular drugs. Crit Rev Ther Drug Carrier Syst (1989) 1.60
Role of chemokines and chemokine receptors in shaping the effector phase of the antitumor immune response. Cancer Res (2012) 1.28
Deletion of the NH2-terminal residue converts monocyte chemotactic protein 1 from an activator of basophil mediator release to an eosinophil chemoattractant. J Exp Med (1996) 1.12
Grape exosome-like nanoparticles induce intestinal stem cells and protect mice from DSS-induced colitis. Mol Ther (2013) 1.09
A pH-responsive cyclodextrin-based hybrid nanosystem as a nonviral vector for gene delivery. Biomaterials (2013) 1.03
pH-Sensitive siRNA nanovector for targeted gene silencing and cytotoxic effect in cancer cells. Mol Pharm (2010) 1.03
Delivery of therapeutic agents by nanoparticles made of grapefruit-derived lipids. Nat Commun (2013) 1.02
Interspecies communication between plant and mouse gut host cells through edible plant derived exosome-like nanoparticles. Mol Nutr Food Res (2014) 1.00
Chemokine receptor CXCR4: role in gastrointestinal cancer. Crit Rev Oncol Hematol (2013) 0.95
Nanomedicine: is the wave cresting? Nat Rev Drug Discov (2013) 0.95
Targeted drug delivery to intestinal macrophages by bioactive nanovesicles released from grapefruit. Mol Ther (2013) 0.91
A pH-sensitive multifunctional gene carrier assembled via layer-by-layer technique for efficient gene delivery. Int J Nanomedicine (2012) 0.91
Emerging concepts and approaches for chemokine-receptor drug discovery. Expert Opin Drug Discov (2010) 0.89
A review of the current scientific and regulatory status of nanomedicines and the challenges ahead. PDA J Pharm Sci Technol (2011) 0.85
Chemokine receptors: attractive targets for drug discovery. Ann N Y Acad Sci (2005) 0.83
T cell responses: kiss and run. Nat Rev Immunol (2014) 0.78